Crosstalk between Microtubule Stabilizing Agents and Prostate Cancer

Area of Science:

• Pharmacology
• Oncology
• Marine Natural Products Chemistry

Background:

• Microtubule-stabilizing agents (MSAs) derived from natural sources are crucial in cancer therapy.
• Docetaxel and cabazitaxel are the only approved agents improving survival in castration-resistant prostate cancer (CRPC).
• MSAs exhibit dual mechanisms of action beyond mitotic arrest, impacting androgen receptor (AR) signaling.

Purpose of the Study:

• To review the anti-prostate cancer efficacy of various MSAs.
• To elucidate the dual mechanisms of action of MSAs in prostate cancer.
• To explore the potential of MSAs as therapeutic options for prostate cancer.

Main Methods:

• Review of preclinical and clinical studies on MSAs in prostate cancer.
• Analysis of the molecular mechanisms of MSAs, including mitotic arrest and AR pathway interference.
• Evaluation of clinical use and outcomes of MSAs in prostate cancer patients.

Main Results:

• MSAs demonstrate efficacy in both AR-positive and AR-null prostate cancer cells.
• Suppression of AR nuclear accumulation is a key mechanism for MSAs in AR-driven CRPC.
• MSAs can be administered alone or in combination for enhanced therapeutic effects.

Conclusions:

• MSAs possess dual mechanisms crucial for treating prostate cancer.
• These agents represent a promising therapeutic strategy for both castration-sensitive and castration-resistant prostate cancer.
• Further investigation into MSAs may lead to improved treatment options for all forms of prostate cancer.